Pattern Separation in Major Depressive Disorder
ConditionMajor Depressive Disorder (MDD)
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-50
SponsorJeffrey Miller
About this trial
This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.
Eligibility criteria
Qualifiers
Age 18-50
Current diagnosis of MDD without psychotic features assessed within three weeks of study enrollment
17-item Hamilton Depression Rating Scale score ≥17 assessed within 3 weeks of study enrollment
Using an effective form of contraception at study enrollment and agrees to continue throughout study participation for individuals of child-bearing potential
Disqualifiers
Currently taking an antidepressant medication at study enrollment
Pregnant or breastfeeding at time of enrollment
Evidence of current unstable medical illness, including liver or renal impairment, or unstable cardiovascular or respiratory illness
QTc interval greater than 500 ms
Trial design
Treatments tested in this trial
- SSRI (escitalopram or sertraline)
- Extended-Release Memantine
- Placebo
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Jeffrey Miller
Lead sponsor
New York State Psychiatric Institute
Sponsor institution
Source ClinicalTrials.gov